Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases
<p>We investigated the performance of ANA-ELISA for CTDs screening and diagnosis and comparing it to the conventional ANA-IIF. ANA-ELISA is a solid-phase immune assay includes 17 ANA-targeted recombinant antigens; dsDNA, Sm-D, Rib-P, PCNA, U1-RNP (70, A, C), SS-A/Ro (52 and 60), SS-B/La, Centr...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513566708596736 |
|---|---|
| author | Omar Suhail Alsaed (14151861) |
| author2 | Laith Ishaq Alamlih (14152893) Omar Al-Radideh (14152896) Prem Chandra (9072038) Samar Alemadi (14152899) Abdul-Wahab Al-Allaf (14158989) |
| author2_role | author author author author author |
| author_facet | Omar Suhail Alsaed (14151861) Laith Ishaq Alamlih (14152893) Omar Al-Radideh (14152896) Prem Chandra (9072038) Samar Alemadi (14152899) Abdul-Wahab Al-Allaf (14158989) |
| author_role | author |
| dc.creator.none.fl_str_mv | Omar Suhail Alsaed (14151861) Laith Ishaq Alamlih (14152893) Omar Al-Radideh (14152896) Prem Chandra (9072038) Samar Alemadi (14152899) Abdul-Wahab Al-Allaf (14158989) |
| dc.date.none.fl_str_mv | 2022-11-22T21:17:16Z |
| dc.identifier.none.fl_str_mv | 10.1038/s41598-021-87366-w |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Clinical_utility_of_ANA-ELISA_vs_ANA-immunofluorescence_in_connective_tissue_diseases/21598221 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Immunology Multidisciplinary |
| dc.title.none.fl_str_mv | Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>We investigated the performance of ANA-ELISA for CTDs screening and diagnosis and comparing it to the conventional ANA-IIF. ANA-ELISA is a solid-phase immune assay includes 17 ANA-targeted recombinant antigens; dsDNA, Sm-D, Rib-P, PCNA, U1-RNP (70, A, C), SS-A/Ro (52 and 60), SS-B/La, Centromere B, Scl-70, Fibrillarin, RNA Polymerase III, Jo-1, Mi-2, and PM-Scl. During the period between March till December 2016 all requests for ANA from primary, secondary, and tertiary care centers were processed with both techniques; ANA-IIF and ANA-ELISA. The electronic medical record of these patients was reviewed looking for CTD diagnosis documented by the Senior rheumatologist. SPSS 22 is used for analysis. Between March and December 2016, a total of 12,439 ANA tests were requested. 1457 patients were assessed by the rheumatologist and included in the analysis. At a cut-off ratio ≥ 1.0 for ANA-ELISA and a dilutional titre ≥ 1:80 for ANA-IIF, the sensitivity of ANA-IIF and ANA-ELISA for all CTDs were 63.3% vs 74.8% respectively. For the SLE it was 64.3% vs 76.9%, Sjogren’s Syndrome was 50% vs 76.9% respectively. The overall specificity of ANA-ELISA was 89.05%, which was slightly better than ANA-IIF 86.72%. The clinical performance of ANA-ELISA for CTDs screening showed better sensitivity and specificity as compared to the conventional ANA-IIF in our cohort.</p><h2>Other Information</h2> <p> Published in: Scientific Reports<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1038/s41598-021-87366-w" target="_blank">http://dx.doi.org/10.1038/s41598-021-87366-w</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_d5cdae6b00082ac320e220c514b8d46f |
| identifier_str_mv | 10.1038/s41598-021-87366-w |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21598221 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseasesOmar Suhail Alsaed (14151861)Laith Ishaq Alamlih (14152893)Omar Al-Radideh (14152896)Prem Chandra (9072038)Samar Alemadi (14152899)Abdul-Wahab Al-Allaf (14158989)ImmunologyMultidisciplinary<p>We investigated the performance of ANA-ELISA for CTDs screening and diagnosis and comparing it to the conventional ANA-IIF. ANA-ELISA is a solid-phase immune assay includes 17 ANA-targeted recombinant antigens; dsDNA, Sm-D, Rib-P, PCNA, U1-RNP (70, A, C), SS-A/Ro (52 and 60), SS-B/La, Centromere B, Scl-70, Fibrillarin, RNA Polymerase III, Jo-1, Mi-2, and PM-Scl. During the period between March till December 2016 all requests for ANA from primary, secondary, and tertiary care centers were processed with both techniques; ANA-IIF and ANA-ELISA. The electronic medical record of these patients was reviewed looking for CTD diagnosis documented by the Senior rheumatologist. SPSS 22 is used for analysis. Between March and December 2016, a total of 12,439 ANA tests were requested. 1457 patients were assessed by the rheumatologist and included in the analysis. At a cut-off ratio ≥ 1.0 for ANA-ELISA and a dilutional titre ≥ 1:80 for ANA-IIF, the sensitivity of ANA-IIF and ANA-ELISA for all CTDs were 63.3% vs 74.8% respectively. For the SLE it was 64.3% vs 76.9%, Sjogren’s Syndrome was 50% vs 76.9% respectively. The overall specificity of ANA-ELISA was 89.05%, which was slightly better than ANA-IIF 86.72%. The clinical performance of ANA-ELISA for CTDs screening showed better sensitivity and specificity as compared to the conventional ANA-IIF in our cohort.</p><h2>Other Information</h2> <p> Published in: Scientific Reports<br> License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1038/s41598-021-87366-w" target="_blank">http://dx.doi.org/10.1038/s41598-021-87366-w</a></p>2022-11-22T21:17:16ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1038/s41598-021-87366-whttps://figshare.com/articles/journal_contribution/Clinical_utility_of_ANA-ELISA_vs_ANA-immunofluorescence_in_connective_tissue_diseases/21598221CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215982212022-11-22T21:17:16Z |
| spellingShingle | Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases Omar Suhail Alsaed (14151861) Immunology Multidisciplinary |
| status_str | publishedVersion |
| title | Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases |
| title_full | Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases |
| title_fullStr | Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases |
| title_full_unstemmed | Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases |
| title_short | Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases |
| title_sort | Clinical utility of ANA-ELISA vs ANA-immunofluorescence in connective tissue diseases |
| topic | Immunology Multidisciplinary |